X

Trial Profile

Phase II Randomized Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
Focus Therapeutic Use
Acronyms PANIRINOX; UCGI28_PANIRINOX

Most Recent Events

24 Oct 2023 First results (n=92) presented at the 48th European Society for Medical Oncology Congress
16 Oct 2023 According to an Amgen media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid.
30 Aug 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com